Israel Englander Shattuck Labs, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 302,598 shares of STTK stock, worth $223,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares

302,598

Previous 201,214 50.39%

Holding current value

$223,922

Previous $243,000 18.11%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.95 - $1.91 $96,314 - $193,643	101,384 Added 50.39%	302,598 $287,000
Q4 2024 Feb 14, 2025	BUY	$1.0 - $1.92 $54,322 - $104,298	54,322 Added 36.98%	201,214 $243,000
Q3 2024 Nov 14, 2024	BUY	$3.0 - $4.85 $149,940 - $242,402	49,980 Added 51.57%	146,892 $512,000
Q2 2024 Aug 14, 2024	SELL	$3.56 - $11.18 $1.84 Million - $5.76 Million	-515,472 Reduced 84.17%	96,912 $374,000
Q1 2024 May 15, 2024	BUY	$7.37 - $10.09 $4.43 Million - $6.07 Million	601,738 Added 5652.24%	612,384 $5.47 Million
Q4 2023 Feb 14, 2024	SELL	$1.37 - $7.24 $62,381 - $329,666	-45,534 Reduced 81.05%	10,646 $75,000
Q2 2023 Aug 14, 2023	SELL	$2.52 - $3.66 $7,812 - $11,346	-3,100 Reduced 5.23%	56,180 $175,000
Q1 2023 May 15, 2023	SELL	$2.5 - $4.72 $87,097 - $164,440	-34,839 Reduced 37.02%	59,280 $174,000
Q4 2022 Feb 14, 2023	SELL	$1.96 - $3.26 $173,193 - $288,066	-88,364 Reduced 48.42%	94,119 $216,000
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.52 $212,009 - $450,111	-81,542 Reduced 30.88%	182,483 $493,000

Others Institutions Holding STTK

# of Institutions

Shares Held

30.9M

Call Options Held

Put Options Held

View Full List

About Shattuck Labs, Inc.

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $31.4M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

More about STTK

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account